Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN™; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts

British Journal of Radiology

Volumn 81, Issue SPECIAL ISSUE, 2008, Pages

  Williams, Kaye J ^a   Telfer, B A ^a   Shannon, A M ^a   Babur, M ^a   Stratford, I J ^a   Wedge, S R ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEDIRANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BLOOD VESSEL DIAMETER; CANCER INHIBITION; CANCER RADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; ENDOTHELIUM; FEMALE; HEMOPERFUSION; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIC CELL; LUNG TUMOR; MOUSE; NECROSIS; NONHUMAN; NUDE MOUSE; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; THERAPY EFFECT; TISSUE SECTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; LUNG NEOPLASMS; MICE; MICE, NUDE; NECROSIS; QUINAZOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55449137493     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/59853976     Document Type: Conference Paper

References (30)

1. Steel GG (Editor). The role of radiotherapy in the management of cancer. In: Basic clinical radiobiology. London, UK: Arnold, 1997:1-3.
2. Wachsberger P, Burd R, Dicker AP. Improving tumour response to radiotherapy by targeting angiogenesis signalling pathways. Hematol Oncol Clin North Am 2004;18:1039-57, viii.
3. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumour effects of ionizing radiation. Cancer Res 1999;59:3374-8.
4. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, et al. Inhibition of vascular endothelial growth factor receptor signalling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001;61:2413-9.
5. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-vascular endothelial growth factor treatment augments tumour radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
6. Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 2001;85:2010-6.
7. Ning S, Laird D, Cherrington JM, Knox SJ. The antiangiogenic agents SU5416 and SU6668 increase the antitumour effects of fractionated irradiation. Radiat Res 2002;157:45-51.
8. Zips D, Krause M, Hessel F, Westphal J, Bruchner K, Eicheler W, et al. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res 2003;23:3869-76.
9. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signalling, combined with radiotherapy: schedule-dependent enhancement of antitumour activity. Clin Cancer Res 2004;10:8587-93.
10. Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, et al. Cooperative antitumour effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 2005;11:5639-44.
11. Li J, Huang S, Armstrong EA, Fowler JF, Harari PM. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 2005;62:1477-85.
12. Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumour cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003;63:3755-63.
13. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumour xenografts. Cancer Res 2001;61:39-44.
14. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, et al. Analysis of biological effects and signalling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222-30.
15. Meyer M, Clauss M, Lepple-Wienhues A, Walterberger J, Augustin HG, Ziche M, et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999;18:363-74.
16. Zeng H, Sanyal S, Mukhopadhyay D. Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 2001;276:32714-9.
17. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
18. Camidge DR, Eckhardt SG, Diab S, et al. A phase I dose-escalation study of weekly IMC-1121B, a fully human antivascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer. Proc Am Soc Clin Oncol 2006;24:abstr 3032.
19. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400.
20. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumour response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-9.
21. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumour hypoxia. Cancer Res 2006;66:3639-48.
22. Riesterer O, Honer M, Jochum W, Oehler C, Ametamey S, Pruschy M. Ionizing radiation antagonizes tumour hypoxia induced by antiangiogenic treatment. Clin Cancer Res 2006;12:3518-24.
23. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
24. Winkler F, Kozin SV, Tong RT, Chae S-S, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumour response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
25. Zips D, Eicheler W, Geyer P, Hessel F, Dorfler A, Thames HD, et al. Enhanced susceptibility of irradiated tumour vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res 2005;65:5374-9.
26. Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signalling: pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 2007;6:599-606.
27. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumour vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-22.
28. Cao C, Albert JM, Geng L, Ivy PS, Sandler A, Johnson DH, et al. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res 2006;66:11409-15.
29. Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, et al. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signalling inhibitorAZD2171 in Calu-6 human lung tumour xenografts. Mol Cancer Ther 2007;6:2198-208.
30. Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 2007;13:4617s-22s.